leadf
logo-loader
viewGenedrive PLC

Genedrive PLC - Result of AGM

RNS Number : 9013U
Genedrive PLC
27 November 2019
 

genedrive plc

("genedrive" or the "Company")

 

Result of AGM

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.

 

For information, details of the proxy voting are shown below:

 

 Resolution

Votes For

Votes For (as % of votes cast)

Votes Against

Votes Against (as % of votes cast)

Votes Withheld

1.      Receive the Annual report and accounts for the Company

22,673,789

100.0%

0

0.00%

515

2.      Approve the Directors' Remuneration Report

21,886,545

96.5%

787,131

3.47%

628

3.      Re-appoint Tom Lindsay as a director

22,674,304

100.0%

0

0.00%

0

4.      Re-appoint Chris Yates as a director

22,674,304

100.0%

0

0.00%

0

5.      Re-appoint David Budd as a director

22,674,304

100.0%

0

0.00%

0

6.      Re-appoint Matthew Fowler as a director

22,674,304

100.0%

0

0.00%

0

7.      Re-appoint Ian Gilham as a director

21,887,370

100.0%

314

0.00%

786,620

8.      Appoint RSM UK as auditors of the Company

22,674,304

100.0%

0

0.00%

0

9.      Directors' authority to allot shares

22,109,087

100.0%

0

0.00%

565,217

10.    Disapplication of pre-emption rights

19,551,681

88.4%

2,556,891

11.57%

565,732

 

The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.genedriveplc.com).

 

- Ends -

 

For further details please contact:

 

genedrive plc

www.genedriveplc.com

David Budd: CEO / Matthew Fowler: CFO

+44 (0)161 989 0245

 

 

 

 

Peel Hunt LLP

+44 (0)20 7418 8900

James Steel / Oliver Jackson

 

 

 

Stanford Capital Partners Limited

+44 (0)20 3815 8880

Patrick Claridge / John Howes

 

 

 

Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

 

Notes to Editors

 

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® mt-RNR1-ID kit has received CE-IVD Certification and will be launched into Europe and other markets following full evaluation by the UK National Health Service. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB).

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGBLBDBGDDBGCR

Quick facts: Genedrive PLC

Price: 118

Market: AIM
Market Cap: £61.34 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: Flat Friday as raft of sobering news dampens spirits

The FTSE is pretty flat this Friday thanks to a week of sobering realities including a surge in COVID-19 cases and the latest borrowing figures with the UK government’s borrowing now at it’s highest amount for August since records began in 1993. Now at a total of £35.9bn in August. Tesco has...

14 hours, 31 minutes ago